Revolution Medicines (NASDAQ:RVMD) versus Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Head to Head Survey

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Revolution Medicines (NASDAQ:RVMD) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, profitability, earnings, dividends and valuation.

Valuation and Earnings

This table compares Kiniksa Pharmaceuticals International and Revolution Medicines”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56 million	8.96	$59.01 million	$0.97	80.21
Revolution Medicines	N/A	N/A	-$1.13 billion	($8.82)	-23.30

Kiniksa Pharmaceuticals International has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Kiniksa Pharmaceuticals International has a beta of 0.05, indicating that its stock price is 95% less volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500.

Insider and Institutional Ownership

53.9% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are owned by insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Kiniksa Pharmaceuticals International and Revolution Medicines’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%
Revolution Medicines	N/A	-88.20%	-57.85%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Kiniksa Pharmaceuticals International and Revolution Medicines, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0	1	9	0	2.90
Revolution Medicines	1	1	19	1	2.91

Kiniksa Pharmaceuticals International currently has a consensus target price of $87.38, indicating a potential upside of 12.31%. Revolution Medicines has a consensus target price of $161.79, indicating a potential downside of 21.29%. Given Kiniksa Pharmaceuticals International’s higher possible upside, analysts clearly believe Kiniksa Pharmaceuticals International is more favorable than Revolution Medicines.

Summary

Kiniksa Pharmaceuticals International beats Revolution Medicines on 9 of the 14 factors compared between the two stocks.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

About Revolution Medicines

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company’s RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.